PharmaNutra S.p.A.: Pfizer Invests in Sucrosomial® Technology
PISA, Italy, April 20, 2020 /PRNewswire/ -- The pharmaceutical company PharmaNutra S.p.A. (Aim Italia -Ticker PHN), leader in the iron-based, nutritional supplements sector, reports on an important new scientific and commercial agreement for the innovative Sucrosomial® Technology patented by the Group.
Pfizer Consumer Healthcare Italy S.r.l., leader in the research, production and commercialisation of medicinal products, has chosen to include the Sucrosomial® Magnesium in the ingredients of its new Multicentrum My Mag. The product, available in Italy from April, will contain three different sources of magnesium including the exclusive formula developed and patented by Alesco srl, a PharmaNutra Group company specialised in the production and distribution of active principles.
This acknowledgement is especially important and prestigious for both the company and the innovative Sucrosomial® Technology, a unique, patented system that enables minerals to cross the gastric environment without obstacles; thus guaranteeing tolerability and high absorption levels. A patent that is already the base of several PharmaNutra brand products, like those in the SiderAL® line (Sucrosomial® Iron) and UltraMag® (Sucrosomial® Magnesium) itself which, in any case, will remain the market's sole product with a 100% Sucrosomial® formula.
The agreement with Pfizer was stipulated by PharmaNutra S.p.A. and Alesco Srl - the Group's two companies that own the trademark - and will enable the global pharma giant to use the "Sucrosomial®" brand and the Italian patent for the mineral-based, orodispersible formulas (No. 0001419366) limited to the Multicentrum My Mag product for the Italian market.
"The agreement we have signed with Pfizer to use our Sucrosomial® Magnesium in their new Multicentrum My Mag is a key step for our company growth and opens stimulating, new scenarios," declares the President Andrea Lacorte. "The fact that a company of Pfizer's stature has acknowledged the validity of our patent and has invested in a direct collaboration with the Group is not just very satisfying. It is also an important growth opportunity for our business, based - as this prestigious agreement confirms once again - on the high value of research."
PharmaNutra S.p.A.
Founded and led by the President Andrea Lacorte and Vice President Roberto Lacorte, PharmaNutra was established in 2003. It develops unique nutritional supplements and innovative nutritional devices, handling the entire production process, from proprietary raw materials to finished product. www.pharmanutra.it
Contact Details:
Gianluca Gracci
Chief Marketing and Communication Officer
Pharmanutra
+39 345 3646330
g.gracci@pharmanutra.it
Investor Relations Pharmanutra
+39 050 7846500
investorrelation@pharmanutra.it
Cristina Tronconi
Spriano Communication Press Office
+39 346 0477901
ctronconi@sprianocommunication.com
Matteo Russo
Spriano Communication Press Office
+39 347 9834881
mrusso@sprianocommunication.com
View original content to download multimedia:http://www.prnewswire.com/news-releases/pharmanutra-spa-pfizer-invests-in-sucrosomial-technology-301042323.html
SOURCE PharmaNutra S.p.A.
